April 8, 2025 10:17 AM EDTUpdated 06:44 PM
News Briefing

Rally­bio ends de­vel­op­ment in rare dis­or­der; Im­mu­ni­ty­Bio rais­es $75M

ENDPOINTS

Plus, news about KalVista, Kak­en Phar­ma­ceu­ti­cal, Lyell and Tan­go Ther­a­peu­tics:

Rally­bio stops work on RLYB212: The com­pa­ny had been test­ing the drug to see if …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

Tome Bio founders wran­gle ‘jump­ing genes’ to cre­ate new pro­gram­ma­ble gene in­ser­tion tool

Biotech’s sur­vival guide; What tar­iffs could mean for phar­ma; Con­gress push­es for $15B fed­er­al biotech in­vest­ment; ...

A service from the Financial Times